LY01015 + fluorouracil + cisplatin

**LY01015 + fluorouracil + cisplatin** is a combination therapy under clinical investigation for the treatment of advanced or metastatic esophageal squamous cell carcinoma. LY01015 is a biosimilar of nivolumab, a monoclonal antibody immune checkpoint inhibitor that targets the programmed death 1 (PD-1) receptor on T cells. By blocking PD-1, LY01015 restores T-cell immune function and potentiates anti-tumor activity. Fluorouracil is an antimetabolite cytotoxic chemotherapy agent that inhibits thymidylate synthase and disrupts DNA synthesis, while cisplatin is a platinum-based chemotherapy that forms DNA crosslinks leading to apoptosis. This combination leverages both immunotherapy (LY01015) and cytotoxic chemotherapy (fluorouracil, cisplatin) to enhance anti-tumor efficacy, with current clinical trials involving patients with advanced esophageal squamous cell carcinoma[7][9].